Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
To plan ahead for inventory purposes
— Pharmacy purchaser, USA
To find manufacturing sources for registration and sales in Sweden
— Pharmaceutical whoesaler, Sweden
For patent and exclusivity due dligience
— Pharma investment firm, USA
For information on drug expiration / generic availability
— Pharmacist, USA
To identify patent expiry dates for Canada and the USA
— Pharmacy services, Canada
Generated: May 23, 2017
| Tradename: | 1 |
| Applicant: | 1 |
| Ingredient: | 1 |
| Patents: | 1 |
| Formulation / Manufacturing: | see details |
| Ingredient-type | Thiazides |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
| Physiological Effect | Increased Diuresis |
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
hydrochlorothiazide; losartan potassium |
TABLET;ORAL | 090528 | ANDA | Torrent Pharmaceuticals Limited | 13668-116 | 13668-116-10 | 1000 TABLET in 1 BOTTLE (13668-116-10) |
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
hydrochlorothiazide; losartan potassium |
TABLET;ORAL | 090528 | ANDA | Torrent Pharmaceuticals Limited | 13668-116 | 13668-116-30 | 30 TABLET in 1 BOTTLE (13668-116-30) |
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 12.5MG;50MG | ||||
| Approval Date: | Oct 6, 2010 | TE: | AB | RLD: | No | ||||
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG;100MG | ||||
| Approval Date: | Oct 6, 2010 | TE: | AB | RLD: | No | ||||
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 12.5MG;100MG | ||||
| Approval Date: | Apr 6, 2010 | TE: | AB | RLD: | No | ||||
To have a global perspective of drug product patents
— Generic drug product company R&D manager, Spain
To get information on drug patent expirations for the UK
— Commercial analyst, UK
For knowledge about patent expiration dates and ongoing patent challenges
— Generic pharma, Canada
To identify drugs that are coming off of patent
— Data analyst, USA
For information on patented drugs and their generic versions
— Policy analyst, South Africa
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
